Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-20
    E.g., 2018-09-20

Archive Search

4 results
12:00 AM, Aug 11, 2008  |  BioCentury | Politics, Policy & Law

New losers in U.K.’s zero sum game

once every 14 days. Bevacizumab is an intravenously infused recombinant human mAb against vascular endothelial growth factor
12:00 AM, May 02, 2005  |  BioCentury | Politics, Policy & Law

Amgen's clinical trial backlash

remaining from AMGN's acquisition of Synergen Inc. in 1994 (see BioCentury, Sept. 8, 1997). The growth factor
12:00 AM, Apr 09, 2001  |  BioCentury | Politics, Policy & Law

Fattening up NIH

researchers can't do the work of biotech companies. He cited IMCL's experience with the epidermal growth factor
12:00 AM, Apr 05, 1999  |  BioCentury | Politics, Policy & Law

Les penseurs

to public health reported that bST could cause a five-fold increase in levels of insulin-like growth factor